Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • ReNeuron

    - PMLiVE

    GSK reveals plans for £400m R&D facility expansion in England

    GSK has formally started the process of seeking a development partner for the expansion plans

    - PMLiVE

    UK biotech Synairgen treats first patient in phase 3 COVID-19 trial

    SNG001 delivers an inhaled formulation of Interferon-beta-1a directly to the lungs

    - PMLiVE

    Chancellor’s ‘coronavirus budget’ also pledges big R&D gains

    Includes measures to help businesses disrupted by the pandemic

    - PMLiVE

    ReNeuron set for recovery after Woodford stake sale

    Edison analyst says sale should help shares to stabilise

    - PMLiVE

    UK biotech funding falls 40% between 2018 and 2019

    Drop attributed to global uncertainty and Neil Woodford scandal

    - PMLiVE

    UK immunology biotech MiroBio launches with $34m fundraising

    Will develop therapeutic antibodies for autoimmune diseases

    - PMLiVE

    Building Europe’s next breakthrough biotechs

    Start Codon's Daniel Rooke on fostering biotech success in Cambridge, UK

    - PMLiVE

    Illumina sets up first ex-US accelerator site in Cambridge

    Boost for UK's golden triangle biotech region

    - PMLiVE

    UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D

    Pilot much more to industry liking, but devil will be in detail

    - PMLiVE

    Celgene says no to Mereo’s cancer drug etigilimab

    UK biotech will focus on rare disease drugs

    - PMLiVE

    Oxford Biomedica gets £53m cash injection from Novo venture arm

    Cell and gene therapy specialist needs to invest to stay ahead

    - PMLiVE

    RNA-focused biotech Storm Therapeutics raises extra £14m

    New head of translational oncology also hired

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links